Register Login
Register to leave comments
  • News bot Jan. 8, 2026, 12:27 p.m.

    📋 ENTRADA THERAPEUTICS, INC. (TRDA) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 07:25:52

    Event Type: Clinical Trial Update

    Event Details:

    Entrada Therapeutics Inc. (TRDA) Announces Clinical Trial Update Entrada Therapeutics Inc. (TRDA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Clinical Stage: clinical study, Phase 1
    • Collaboration: GLOBE NEWSWIRE
    • Updated Timeline: Q3 2027, Q2 2026
      • anticipated into Q3 2027
      • targeting Usher syndrome, an inherited retinal disorder with a profound unmet clinical need,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “2026
      • expected in the second quarter of 2026

    🔬 Clinical Development Pipeline (ENTRADA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    ENTR-601-44 - matching placebo DRUG Phase PHASE1 Duchenne Muscular Dystrophy (DMD) ClinicalTrials.gov
    ENTR-601-45 - matching placebo DRUG Phase PHASE1 Duchenne Muscular Dystrophy (DMD) ClinicalTrials.gov
    ENTR-601-45 DRUG Phase PHASE1 Duchenne Muscular Dystrophy (DMD) ClinicalTrials.gov
    ENTR-601-44 DRUG Phase PHASE1 Duchenne Muscular Dystrophy (DMD) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Entrada Therapeutics Inc.
    • CIK: 0001689375
    • Ticker Symbol: TRDA
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories